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A B S T R A C T
Purpose: To determine the prevalence of active convulsive epilepsy and treatment gap in two Urban
slums in Enugu South East Nigeria.
Methods: A 3 phase cross-sectional descriptive study was done to survey individuals 15 years in
2 slums in Enugu, South East Nigeria.
Results: The prevalence of epilepsy was 6.0 (95% CI: 5.9–6.0) per 1000 (men 4.4/1000, 95% CI: 2.3–6.4,
women 7.8/1000, 95% CI: 4.9–10.4), p = 0.06. The peak age of active convulsive epilepsy was 40–44 years
(11.2 per 1000) with two smaller peaks at 25–29 and 50 years. The age and sex adjusted prevalence
using WHO standard population and 2006 Nigerian census population were 5.9 per 1000 (95% CI: 4.0–
7.9) and 5.4 per 1000 (95% CI: 3.4–7.4).
Conclusion: The prevalence of epilepsy is high in urban slums in Enugu. Nationwide studies should be
done to ﬁnd out the true prevalence in the country.
 2016 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Contents lists available at ScienceDirect
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Epilepsy is a common neurological disorder and one of the most
prevalent non-communicable disorders affecting about 70 million
[1] people worldwide. In the African continent, epilepsy remains a
major public health problem, not only because of the impact on
health but also the socio-cultural, psychological, and economic
connotations. Active epilepsy is estimated to affect 4.4 million
people in Sub-Saharan Africa (SSA), whilst lifetime epilepsy is
estimated to affect 5.4 million with the peak in the 3rd decade of
life [2]. The high prevalence of epilepsy, especially in young adults,
has important consequences for both the workforce and commu-
nity structures. In a recent report from South East Nigeria, the
prevalence of active convulsive epilepsy was estimated to be
4.3 per 1000 (95% CI: 2.7–5.9) [3].* Corresponding author at: Department of Medicine, University of Nigeria
Teaching Hospital, PMB 01129, Enugu, Nigeria. Tel.: +234 8036769469.
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the overall estimate of treatment gap is 56/100 (95% CI: 31.1–
100.0) [4]. Apart from high prevalence rate and large treatment
gap, trends in SSA suggest a large proportion of symptomatic
epilepsy, higher rural prevalence, low levels of awareness and high
levels of stigma [1,3,5–7].
Though a number of studies provide prevalence data about
epilepsy in Nigeria [3,8,9], no study has focused on special
populations such as urban slum dwellers.
2. Methods
This study was carried out in Agu-Abor and Ugbodogwu slums
in Enugu East Local Government Area of Enugu State, South East
Nigeria. Agu-Abor has an estimated adult population of 3000–4000
while Ugbodowu has an estimated population of 5000–7000
(based on church and local records). The overall population of
Enugu East Local government is 145, 905 based on 2006 census
count [10]. These settlements are located at the foot of Udi hills and
together occupy an area of about 2.5–5 km2 about 1–2.5 km from
the city center. The nearest tertiary hospital. Agu-abor has noserved.
B.A. Ezeala-Adikaibe et al. / Seizure 35 (2016) 100–105 101primary health center while Ugbodogwu has in addition to a
primary school a secondary school and a primary health centers.
People also access care from government health institutions within
the city.
3. Study design
A 3 phase cross-sectional descriptive study was performed to
survey the adult population (15 years of age). The sample size
was determined using the formula. n = DZ1a/2
2P(1  P)/d2
(Lwanga and Lemeshow 1991) [11], where d = absolute preci-
sion = 0.00215 (for a sample size lower than 5%), P = prevalence of
4.3 per 1000 = 0.00433, D = design effect = 2, Z1a/2 = standard
normal deviate corresponding to 5% level of signiﬁcance (2 sided
test) = 1.96. The calculated sample size was 7116. Assuming 10%
attrition, a minimum sample size of 7910 was used.
The ﬁrst phase of the study was preceded by sensitization
meetings in the community which included both religious and
elected leaders, a 4-day training program with a review of the
questionnaire, demonstration of interview technique, and back-
demonstration by the interviewer. The study questionnaire was
forward- and back-translated into Igbo and reviewed by bilingual
individuals for accuracy. A clinic-based validation of a subset of a
random sample of 50 screened individuals (25 positives, 25 nega-
tives) was assessed by a neurologist (BAE) (blinded to screening
results) who conducted a complete neurologic history, physical
examination, and review of prior medical records before deter-
mining if the patient met the case deﬁnition for active convulsive
epilepsy. The Igbo adapted questionnaire exhibited an overall 100%
sensitivity and 96% (95% CI: 96–100) speciﬁcity (see below table). A
false-positive screen occurred in an individual who had experi-
enced repeated syncope. The positive predictive value of the
instrument was 96.2% (95% CI: 91–100). Validation of the
screening questionnaire (Igbo version) was carried out in
Neurology clinic of the department of medicine, University of
Nigeria Teaching Hospital Enugu.
Results of validation study of the Igbo version of the questionnaire.
True positives
(%) (a)
False positives
(%) (b)
False negatives
(%) (c)
True negatives
(%) (d)
Epilepsy 25 (100) 1 0 24
Diagnostic accuracy = (a + d)/N = 98%.
Sensitivity = a/(a + c) = 100%.
Speciﬁcity = d/(b + d) = 96%.
Positive predictive value = a/(a + b) = 96.2%.
Negative Predictive value = d/(c + d) = 100.
During the second phase of the study, a door-to-door survey by
teams of trained research assistants was performed. In this phase
the research instrument for screening neurological disorders in the
community by Osuntokun et al. [9] was administered to identify
persons with at least one life time episode of convulsion. Each
questionnaire had a unique identiﬁcation number and the three
letter initials of the subjects clearly written on them during the
house to house interview. Using a simple random sampling
technique all consecutive consenting individuals in each of the
settlements were interviewed until the minimum sample size was
reached. The WHO STEPS instrument [12] was used to collect data
on selected socio-demographic characteristics and lifestyle beha-
viors. The inhabitants of Agu-abor were surveyed over a 4-week
period (August 12–September 9, 2013), while Ugbodogwu
inhabitants were surveyed between November 25 and December
21, 2013. A positive history of convulsions at this stage resulted in
the invitation of the individual to the clinic for the third phase of
the study.The third phase of the study was conducted at temporary clinics
at the study sites. Cases identiﬁed during the second phase were
interviewed by the primary investigator and a doctor not below the
rank of a senior registrar in the department of medicine. The 2nd
and 3rd stages ran concurrently and lasted for 6 weeks. Only
subjects who had at least one lifetime episode of convulsion who
reported to the clinic were included in this stage.
The exclusion criteria were refusal to participate and lack of
basic knowledge of Igbo language. A minimum age of 15 years was
chosen during the design of the study for three reasons: (1) to avoid
recruiting students (primary and junior secondary) who were
having end of year examinations at that time; (2) the anticipated
difﬁculty in getting consent from parents; (3) the validation study
was performed only in subjects within the same age group. The
study of active convulsions was chosen to reduce the possibility of
recall bias especially among older individuals. Non Igbos were
excluded in view of the questionnaire only being validated in Igbo.
Furthermore all the investigators and community health workers
were Igbos.
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The study protocol was reviewed on behalf of State (Enugu
State) Ministry of Health by the Ethics committee of the Enugu
State University of Science and Technology Teaching Hospital and
University of Nigeria Teaching Hospital, Enugu. All participants
gave their informed consent after reading or having the consent
form read for them.
To encourage subject participation free basic medical checks
such as blood pressure, fasting blood glucose, urine analysis and
electrocardiogram were offered to all for free at the clinic. During the
third phase all cases with a history of a convulsion were reviewed.
4. Case deﬁnition
An active epilepsy case was deﬁned as anyone on treatment for
epilepsy or with a history of recurrent seizures with the most
recent occurring in the past 5 years if the seizure(s) was not
Table 1
Sex and age distribution with socio-demographics.
Males Female Total
N (%) N (%) N (%)
Age groups (years)
15–19 548 (13.2) 663 (16.2) 1211 (14.7)
20–24 704 (17) 792 (19.4) 1496 (18.2)
25–29 619 (15) 686 (16.8) 1305 (15.9)
30–34 497 (12) 526 (12.9) 1023 (12.4)
35–39 414 (10) 395 (9.7) 809 (9.8)
40–44 468 (11.3) 336 (8.2) 804 (9.8)
45–49 260 (6.3) 214 (5.2) 474 (5.8)
50 630 (15.2) 476 (11.6) 1106 (13.4)
Level of education
No formal education 23 (0.6) 40 (1) 63 (0.8)
Primary 489 (11.8) 462 (11.3) 951 (11.6)
Secondary 2169 (52.4) 2177 (53.7) 4346 (52.8)
Tertiary 1459 (35.2) 1409 (34.5) 2868 (34.9)
#Occupation
Students/apprentices 1525 (36.8) 1704 (41.7) 3229 (39.2)
Traders (business) 1033 (52) 1299 (31.8) 2332 (28.3)
yArtisans 880 (21.3) 313 (7.7) 1193 (14.3)
Ofﬁce/factory workers 469 (11.3) 450 (11.0) 919 (11.2)
Farmers 117 (2.8) 135 (3.3) 252 (3.1)
Unemployed 46 (1.1) 145 (3.5) 191 (2.3)
Pensioners 53 (1.3) 17 (0.4) 70 (0.9)
Others 17 (0.4) 25 (0.6) 42 (0.5)
Social habits
Use tobacco* 557 (13.5) 169 (4.1) 726 (8.8)
yyAlcohol** 68 (1.6) 55 (1.3) 123 (1.5)
aMedical comorbidities
Head injury with LOC 64 (1.5) 75 (1.8) 139 (1.7)
Febrile convulsion 37 (0.9) 44 (1.1) 81 (1)
cMental illness 16 (0.4) 43 (1.1) 59 (0.7)
bHypertension 236 (5.7) 335 (8.2) 571 (6.9)
Diabetes 163 (3.9) 158 (3.9) 321 (3.9)
Stroke 43 (1) 39 (1) 82 (1)
Family history of convulsions 37 (0.9) 72 (1.8) 109 (1.3)
Total 4133 (50.2) 4095 (49.8) 8228 (100)
a Previous hospital diagnosis done by a doctor.
b History of hypertension, use of antihypertensive.
c Reciving or recived treatment from a psychiatric hospital or psychiatrist.
# Occupation was deﬁned as the primary job which takes at least 50% of the
working hours in a week. (what is your primary job which accounts for more than
50% of your working time?).
* Use of all forms of tobacco (do you smoke cigarette, use snuff or chew tobacco?).
** Drinking more than 14 units of alcohol per week for women and 21 for men
[20].
y An artisan was deﬁned as skilled manual laborers such as masons, mechanics,
tailors, welders and other crafts.
yy Alcohol use and quantity was deﬁned as (mean quantity) the consumption of
any alcoholic beverage (beer, gin, stout, local brew) in a week.
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any other acute illness such as stroke or head injury or during
delivery or third trimester of pregnancy. Tobacco use was deﬁned
as the use of (any or all) cigarettes, snuff and chewing tobacco in
the past 4 weeks. Alcohol use and quantity was deﬁned as (mean
quantity) the consumption of any alcoholic beverage (beer, gin,
stout, local brew) in a week. The safe limit of alcohol was deﬁned
based on WHO guidelines of 21 units for men and 14 units for
women per week [13]. Occupation was deﬁned as the primary job
which takes at least 50% of the working hours in a week. An artisan
was deﬁned as skilled manual laborers such as masons, mechanics,
tailors, welders, metal workers and other crafts. A trader was
deﬁned as small scale businessman or businesswoman.
Medical comorbidities (hypertension, diabetes, and stroke)
were deﬁned using standard criteria or past medical history
diagnosed by a qualiﬁed personnel (doctors).
5. Statistical methods
For database management and statistical analyses, we used the
SPSS version 21 (IBM Corporation, New York, USA). Data were
presented in tables. For continuous variables, mean values and 95%
conﬁdence intervals were calculated. Prevalence of epilepsy and
lifetime convulsion in the subjects was expressed as per 1000 and
percentages and the odds ratio calculated. Mean values were
compared using the independent t test. Proportions were
compared using McNemar’s test and Chi squared test where
applicable. In all, p value of <0.05 was regarded as statistically
signiﬁcant. Conclusions were drawn at the level of signiﬁcance. The
conﬁdence level was kept at 95%.
6. Results
6.1. Description of the study population
8259 individuals consented and were interviewed; however
only 8228 (99.6%) were analyzed. This comprised of 4133 (50.2%)
men and 4095 (49.8%) women, with a male to female ratio of 1:1.
306/8228 (135 males and 171 females) individuals responded
positively to the screening questions on epilepsy and were
clinically interviewed during the survey period with a diagnosis
of active epilepsy being made in 49 (16%). The age of the
respondents ranged from 15 to 95 years with a mean age of 33.0 (CI
95% CI: 32.7–33.3) years. Males were signiﬁcantly older than
females; males, 34.2 (95%, CI 33.75–34.61) vs females, 31.8 (95%, CI
31.4–32.2) years. p < 0.0001. The age distribution and baseline
characteristics of the population are shown in Table 1.
6.2. Social habits and medical history
The sex distribution of tobacco (13.5%) and alcohol use (1.6%) is
shown in Table 1. Sixty four (1.5%) reported a history of head injury
with loss of consciousness. The proportion of people who had
febrile seizures, stroke and mental illness are shown in Table 1. The
commonest comorbidity was hypertension (5.7%).
7. Epilepsy
A total of 306 (3.7%) individuals reported a lifetime history of at
least one convulsion. The distribution of lifetime prevalence of
convulsions is shown in Table 2. It peaked at 50 years. High rates
were reported among people with a, history of psychiatric
treatment (mental illness) (49.2%) and in those with family history
of convulsions (36.7%).
The prevalence of epilepsy was 6.0 (95% CI: 5.9–6.0) per 1000;
similar in men (4.4/1000, 95% CI: 2.3–6.4) and women (7.8/1000,95% CI: 4.9–10.4), p = 0.06, Table 2. The male to female ratio was
0.6:1. The age and sex gender-speciﬁc rates are shown in
Table 3. The prevalence of epilepsy increased with age reaching
11.2 per 1000 at 40–44 years with two smaller peaks at 25–29 and
50 years. The peak age speciﬁc prevalence for men (9.7 per 1000,
95% CI: 9.2–10.1) was 35–39 years and 40–44 years for females
(17.9 per 1000, 95% CI: 17.1–18.63). The age and sex adjusted
prevalence using WHO standard population and Enugu East
2006 population were 5.9 per 1000 (95% CI: 4.0–7.9) and
5.4 per 1000 (95% CI: 3.4–7.4) (Table 4). The sex adjusted
prevalence is shown in Table 5. The sex adjusted prevalence in
women at 8.0 (95% CI: 4.6–11.7) per 1000 was almost twice that of
men (3.9 (95% CI: 1.6–6.3) per 1000).
Forty three (87.8%) were known epilepsy patients while 6 were
newly diagnosed. All the previously diagnosed cases were also on
treatment. Newly diagnosed cases were referred to the
state hospital for follow-up. EEG was ordered for all the subjects
however none attended for the investigation. Brain CT scans were
not performed. Based on history alone focal onset seizures
Table 2
Distribution of epilepsy and lifetime prevalence of convulsions.
Lifetime
convulsions
95% CI Epilepsy 95% CI
N (%) N (%)
Age groups (years)
15–19 39 (3.2) 2.21–4.19 4 (3.3) 3.21–3.34
20–24 40 (2.7) 1.88–3.52 5 (3.3) 3.27–3.42
25–29 41 (3.1) 2.16–4.04 8 (6.1) 6.01–6.25
30–34 28 (2.7) 1.71–3.69 5 (4.9) 4.75–5.02
35–39 39 (4.8) 3.33–6.27 9 (11.1) 10.87–11.38
40–44 28 (3.5) 2.23–4.77 9 (11.2) 10.94–11.45
45–49 17 (3.6) 1.92–5.28 2 (4.2) 3.95–4.49
50 74 (6.7) 5.23–8.17 7 (6.3) 6.19–6.47
Social habits
Use tobacco* 67 (9.2) 7.1–11.3 9 (12.4) 12.10–12.70
yyAlcohol** 2 (1.6) 0.62–3.82 – –
aMedical comorbidities
Head injury
with LOC
29 (20.9) 14.14–27.66 4 (28.8) 26.42–31.13
cMental illness 29 (49.2) 36.44–61.96 5 (84.7) 75.49–94.00
bHypertension 70 (12.3) 14.99–9.61 11 (19.3) 18.79–19.74
Diabetes 31 (9.7) 6.46–12.94 11 (34.3) 33.16–35.39
Stroke 23 (28) 37.72–18.28 9 (109.8)1 102.28–117.23
Family history
of convulsions
40 (36.7) 27.65–45.75 10 (91.7) 86.56–96.93
Total 306 (3.7) 3.29–4.11 49 (5.96) 5.94–5.97
a Previous hospital diagnosis done by a doctor.
b History of hypertension, use of antihypertensive.
c Receiving or received treatment from a psychiatric hospital or psychiatrist.
* Use of all forms of tobacco (Do you smoke cigarette, use snuff or chew tobacco?)
** Drinking more than 14 units of alcohol per week for women and 21 for men
[20].
yy Alcohol use and quantity was deﬁned as (mean quantity) the consumption of
any alcoholic beverage (beer, gin, stout, local brew) in a week.
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in 10 (20.4%) cases.
8. Discussion
This is a cross-sectional descriptive study of the prevalence of
active epilepsy in an urban slum in South East Nigeria. Our set
hypothesis was that we would see a high prevalence of epilepsy in
a setting with poor public health indicators.
The age-standardized prevalence of active epilepsy in adults
based on WHO standard population and Enugu East 2006 census (6/
1000 (95% CI: 4.0–7.9) and 5.4/1000 (95% CI: 3.4–7.4) respectively)
and the crude prevalence rate of 6.0/1000 (95% CI: 5.9–6.0), are
considerably lower than the median prevalence of 15/1000
previously reported from SSA [14] but slightly higher than 4.3/Table 3
Age and sex distribution of epilepsy.
Age group Epilepsy Epilepsy p-valuey
Males Females
(N %, 95% CI) (N %, 95% CI)
15–19 2 (3.6, 3.43–3.87) 2 (3, 2.85–3.18) 0.848
20–24 3 (4.3, 4.08–4.44) 2 (2.5, 2.40–2.65) 0.561
25–29 1 (1.6, 1.49–1.74) 7 (10.2, 9.92–1.05) 0.072
30–34 2 (4, 3.77–4.27) 3 (5.7, 5.42–5.98) 1.000
35–39 4 (9.7, 9.2–10.12) 5 (12.7, 12.10–13.21) 0.685yy
40–44 3 (6.4, 6.08–6.74) 6 (17.9, 17.08–18.63) 0.119
45–49 1 (3.8, 3.38–4.31) 1 (4.7, 4.05–5.30) 0.700
50 2 (3.2, 3.00–3.35) 5 (10.5, 10.08–10.92) 0.128
Total 18 (4.4, 2.3–6.4) 31 (7.8, 4.9–10.2) 0.057
y McNemar’s test.
yy Chi squared test.1000 (95% CI: CI 2.7–5.9) reported in the same region [3]. An earlier
study using the same instrument in South West Nigeria reported a
prevalence rate of 5.3/1000 similar to the index study [15].
Reported prevalence rates from community based studies in
SSA are variable [2,14]. Among a population of 586,607 residents in
a study covering ﬁve countries the prevalence of epilepsy varied
between sites and ranged from 7.8 to 14.8 per 1000, much higher
than reported in the index study [16]. Hence, epilepsy in Africa is
better reviewed on a regional than continental basis as risk factors
vary within and between ethnic entities because of differences in
cultural, religious and economic practices. The wide variation in
the frequency of epilepsy in the continent could also arise from the
use of different deﬁnitions of epilepsy, the nature of epilepsy
studied as well as differences in the samples of population studied.
Other factors may include treatment gap [2,3,17] which may bring
a selective survival bias, stigmatization and urban rural drift
[18,19].
The age distribution of active epilepsy in this study reveals an
older peak than has been reported in Nigeria [3,8,9] and other
developing countries [20–22]. Active epilepsy increased with age
and peaked at 35–44 age group; a distribution which overlaps with
the overall pattern in the continent where active convulsive
epilepsy peaks in the 20–29 age group and the 40–49 age group
[2]. This second peak corresponds to our ﬁnding and may reﬂect
the effects of trauma, HIV, central nervous system infections and
stroke. The age-speciﬁc prevalence of epilepsy identiﬁed may
suggest a unique underlying cause for the high-rates of epilepsy
seen in this area. A total of 306 (3.7%) individuals reported a
lifetime history of at least one convulsion which may reﬂect the
high prevalence of epilepsy risk factors. We are not aware of any
study in the continent that has focused on the lifetime prevalence
of convulsions.
Among the epilepsy cases identiﬁed in this survey, females
predominated overall although the difference was not statistically
signiﬁcant. This is surprising, especially in light of more rigorous
screening applied in the study. Some explanation may be
plausible: women and older individuals (with or without epilepsy)
are more likely to be at home during the study. Further, women are
known to have a better health seeking behavior than men hence
are more likely to present themselves for interview.
This ﬁnding was similar to some studies from within the
continent and different from others [3,8,9,21–24]. Some studies
have reported higher prevalence of epilepsy in women
[24,25]. Similar to our index study, no gender differences were
identiﬁed in North Africa [26] and Nigeria [9]. It has been argued
that these gender differences may represent different aetiologies
and gender-dependent risk factors or maybe simply an artifact of
case ascertainment or competing mortality risks [23]. The reversal
of the male to female trend after 24 years is similar to ﬁndings from
Zambia [23]. This trend occurring after childbearing age is
intriguing and may offer a clue as to the underlying etiology of
epilepsy in the region. Repeated cases of eclampsia may be
wrongly interpreted as epilepsy especially among previously
diagnosed individuals.
In our study 109 (1.3%) of the population studied and 10 (20.4%)
of individuals with epilepsy reported a family history of convul-
sion. In Sub-Saharan Africa, on average, a family history of epilepsy
was noted in 6%–60% [14]. Consanguineous marriage is forbidden
by culture in South East Nigeria however, stigmatization and
marginalization of patients with epilepsy may potentially force
them to intermarry thereby expanding the patient pool by
promoting the genetic transmission of epilepsy.
This study provided estimates of epilepsy prevalence for an urban
slum – an area with no previously available population-based
epilepsy data. If our estimate is applied to all of Enugu East (total
population 145,905), then close to 861 people aged 15 years and
Table 4
Age adjusted prevalence of epilepsy (%).
Crude
prev (%)
ES* weighted
population
ES* expected
cases
Adjusted
prevalence (%)
WHO weighted
population
WHO
expected
cases
Adjusted
prevalence (%)
<15 – – –
15–19 3.6 973 3 3.1 (0.4–6.6) 697 2 2.7 (1.1–6.8)
20–24 4.3 931 3 3.2 (0.4–6.9) 676 2 3.0 (1.1–7.1)
25–29 1.6 723 4 5.5 (0.1–10.9) 652 4 6.1 (0.1–12.1)
30–34 4.3 531 3 5.6 (0.7–12.0) 626 3 4.8 (0.6–10.2)
35–39 9.7 455 5 11.0 (1.4–20.6) 588 6 10.2 (2.1–18.3)
40–44 6.4 392 4 10.2 (0.3–20.2) 542 6 11.1 (2.3–19.9)
45–49 3.8 350 1 2.9 (2.7–8.4) 497 2 4.0 (1.5–9.6)
50 3.2 861 5 5.8 (0.7–10.9) 1796 11 6.1 (2.5–9.7)
Total 6.0 5216 28 5.4 (3.4–7.4) 6074 36 5.9 (4.0–7.9)
Table 5
Sex adjusted prevalence of Epilepsy (%).
Males Crude
prev. (%)
ES* weighted
population
ES* Expected
cases
Adjusted prevalence
(%)
Females Crude
prev. (%)
ES weighted
population
ES Expected
cases
Adjusted
prevalence (%)
15–19 3.6 454 2 4.4 (1.7–10.5) 3.2 450 1 2.2 (2.1–6.6)
20–24 4.3 421 2 4.8 (1.8–11.3) 2.5 417 1 2.4 (2.3–7.1)
25–29 1.6 326 1 3.1 (2.9–9.1) 10.2 323 3 9.2 (1.2–19.7)
30–34 4.3 232 1 4.3 (4.1–12.7) 5.7 229 1 4.3 (4.2–12.9)
35–39 9.7 216 2 9.2 (3.5–22.0) 12.7 214 3 14.0 (1.7–29.8)
40–44 6.4 209 1 4.9 (4.6–14.1) 17.9 207 4 19.3 (0.6–38.1)
45–49 3.8 213 1 4.7 (4.5–13.9) 4.7 211 1 4.7 (4.5–14.0)
50 3.2 722 2 2.8 (1.1–6.6 10.5 715 8 11.1 (3.5–18.9)
Total 4.4 2793 11 3.9 (1.6–6.3) 7.8 2767 22 8.0 (4.6–11.7)
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with most occurring in individuals 35–44 years. In this study non
Igbo speaking individuals and children younger than 15 years were
excluded. The exclusion of younger children is likely to underesti-
mate the overall burden of epilepsy and especially lifetime
prevalence of convulsions. The impact of excluding non Igbos in
this study is difﬁcult to quantify. The prevalence of epilepsy among
them is not likely to be higher based on local experiences from
epilepsy clinics in the city. It is important however to note that most
rural to urban migration are more likely to end in slums such as areas
studied.
The diagnosis of epilepsy or seizures is usually prompted by
symptoms noticed by the patient or their care givers. This is
particularly a problem in focal seizures and absence seizures and
other rare forms of epilepsy. On many occasions a diagnosis is only
made in retrospect following presentation with a generalized
seizure or after many years [27,28]. In SSA, cultural and religious
beliefs make this problem even more acute and such patients may
be taken to the psychiatrists, herbal homes and prayer houses.
On the other hand a descriptive diagnosis of epilepsy may lead
to over diagnosis with the most common differential diagnoses
being dissociative seizures and syncope [29]. With the dearth of
qualiﬁed specialists in SSA the overall likelihood of misdiagnosis is
likely to be much higher. The combined use of EEG and clinical data
allows the reclassiﬁcation of some cases of clinically diagnosed
generalized seizures to focal seizures evolving to a bilateral
convulsive seizure [24] suggesting a possibility of even higher rates
of focal seizures in the study. None of our subjects had an EEG.
The overall treatment gap of 12.2% (n = 6/49) found in our study
was much lower than of 76% found in the region [3]. There is a
dramatic disparity in the treatment gap in SSA countries [30] as
well as between rural and urban settings. A low treatment gap of
23% has been reported in Senegal [31]. Like in Senegal where a low
treatment gap was attributed to the presence of a nearby
Senegalese League Against Epilepsy, the Nigerian League Against
Epilepsy is based in Enugu from where it carries most of its publicawareness programs. This ﬁnding therefore supports the useful-
ness of such organizations in epilepsy care.
A number of limitations can be highlighted with regard to this
study. The instrument used could detect equally both generalized
tonic clonic seizures and focal seizures evolving to convulsive
seizures. Nevertheless, individuals with dyscognitive or myoclonic
seziures may probably be under recognized. The use of a 2-stage
interview reduced this to the barest minimum. Patients may not be
aware of the nature of attacks hence our classiﬁcation of seizures
may not be very accurate.
Epilepsy-associated stigma may result in a reluctance to admit
the disorder resulting in further underestimation of the number of
prevalent cases. The number of men with epilepsy might have been
underestimated because they were more likely to be out during the
day. Children less than 15 years (with higher burden of epilepsy)
and non Igbo speaking subjects were excluded. The analysis of
antiepileptic drug use was restricted to the current therapy which
were veriﬁable hence our estimate of treatment gap may even be
lower.
9. Conclusions
This survey demonstrates that active epilepsy is common in a
two Urban Slums in Enugu South East Nigeria. The prevalence of
epilepsy increased with age reaching 11.2 per 1000 at 40–44 years
with two smaller peaks at 25–29 and 50 years and was higher
among individuals with medical comorbidities. Nationwide
studies should be performed to ﬁnd out the true prevalence in
the country and the possible role of genetics in subjects with a
family history of epilepsy.
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